IQVIA Holdings Inc. (IQV) Advances Clinical Research and Data Capabilities to Drive Growth

On March 3, analysts at RBC Capital initiated coverage of IQVIA Holdings Inc. (NYSE:IQV) with an Outperform rating and a $221 price target.

According to RBC Capital analyst Ryan Halsted, the company is making significant progress in clinical trial activity. The research firm expects the company to benefit from an inflection in contract research organization and data analytics capabilities. The company already boasts over 64 petabytes of data and relationships with large pharmaceutical companies.

The huge troves of proprietary data is seen as a critical differentiator. RBC Capital also expects the integration and adoption of artificial intelligence in life sciences to further strengthen the company’s outlook.

The positive outlook also comes on the heels of IQVIA Holdings entering into an agreement to acquire certain discovery services assets from Charles River Laboratories. The acquisition includes five sites for in vitro discovery services.

IQVIA Holdings Inc. (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. It focuses on using data, technology, and human expertise to improve healthcare outcomes, often referred to as "Human Data Science."

While we acknowledge the potential of IQV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Best Gold Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.